Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Gynecol Oncol. 2021 Apr 22;161(3):720–726. doi: 10.1016/j.ygyno.2021.04.016

Table 3:

Treatment-Related Significant Adverse Events

Adverse Event Grade 1 Grade 2 Grade 3 Total Number of Patients (N=101)
Proteinuria 1 (1%) 0 0 1 (1%)
Bowel obstruction 0 0 3 (3%) 3 (3%)
Hypertension 14 (14%) 21 (21%) 10 (10%) 45 (45%)
Stroke 0 1 (1%) 0 1 (1%)
Thrombosis 0 2 (2%) 0 2 (2%)
Gastrointestinal bleeding 1 (1%) 1 (1%) 0 2 (2%)
Edema 0 1 (1%) 0 1 (1%)